drugset / Trial / NCT02737787
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.
Timeline
- Start
- 2016-04
- Primary completion
- 2023-04-06
- Completion
- 2023-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NY-ESO-1 Vaccine | Vaccine | 1 ml | — |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | WT1 Vaccine | Vaccine | — | — |